Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACORNYSE:CSUNASDAQ:ORMP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$11.13$0.61▼$24.20$820K1.4119,299 shs416,900 shsCSUCapital Senior Living$31.66$8.62▼$58.94$73.49M2.1532,471 shs77 shsORMPOramed Pharmaceuticals$2.37+0.9%$2.86$1.67▼$5.25$95.22M1.81116,821 shs40,834 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%-94.63%-96.12%-92.66%CSUCapital Senior Living0.00%0.00%0.00%0.00%0.00%ORMPOramed Pharmaceuticals+0.85%+1.72%-14.13%+4.41%+8.22%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACORAcorda TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACSUCapital Senior LivingN/AN/AN/AN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda TherapeuticsN/AN/AN/AN/ACSUCapital Senior Living3.00Buy$3,400.00∞ UpsideORMPOramed PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$117.63M0.00N/A0.02($127.17) per share0.00CSUCapital Senior Living$383.86M0.00N/AN/A($131.19) per share0.00ORMPOramed Pharmaceuticals$1.34M71.67N/AN/A$4.04 per share0.59Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%5/9/2024 (Estimated)CSUCapital Senior Living-$295.37M$49.780.67N/AN/A40.40%N/A-5.64%N/AORMPOramed Pharmaceuticals$5.53M$0.1416.93∞N/AN/A-7.15%-5.70%5/9/2024 (Estimated)Latest CSU, ORMP, and ACOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/6/2024Q4 2023ORMPOramed Pharmaceuticals-$0.12-$0.08+$0.04-$0.49N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/ACSUCapital Senior LivingN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.070.330.26CSUCapital Senior LivingN/A0.110.11ORMPOramed PharmaceuticalsN/A3.063.06OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%CSUCapital Senior Living62.65%ORMPOramed Pharmaceuticals12.73%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%CSUCapital Senior Living5.46%ORMPOramed Pharmaceuticals12.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataCSUCapital Senior Living3,4162.19 million2.07 millionOptionableORMPOramed Pharmaceuticals1240.52 million35.66 millionOptionableCSU, ORMP, and ACOR HeadlinesSourceHeadlineBML Capital Management LLC Has $2.91 Million Stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)marketbeat.com - April 24 at 5:18 AMOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Large Growth in Short Interestmarketbeat.com - April 15 at 4:39 PMORMP Apr 2024 2.500 putfinance.yahoo.com - March 16 at 1:52 AMOramed Pharmaceuticals Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - March 9 at 2:05 PMOramed to reinitiate pivotal type 2 diabetes trial after Phase III flopmsn.com - February 21 at 6:04 PMOramed Pharmaceuticals Inc.: Oramed Letter to Shareholdersfinanznachrichten.de - February 20 at 4:02 PMOramed Letter to Shareholdersprnewswire.com - February 20 at 8:30 AMORMP: Multiple Potential Applications for Proprietary Oral Protein Delivery Platformfinance.yahoo.com - January 24 at 1:21 PMOramed Pharmaceuticals (ORMP) Price Target Increased by 36.51% to 4.39msn.com - November 28 at 8:11 PMOramed Pharmaceuticals (ORMP) Price Target Increased by 57.50% to 3.21msn.com - November 2 at 10:07 AMOramed Pharmaceuticals (NASDAQ:ORMP) investors are sitting on a loss of 63% if they invested a year agofinance.yahoo.com - October 6 at 1:58 PMOramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Companyfinance.yahoo.com - September 21 at 7:02 PMOther OTC Pharmaceuticals - Indonesiastatista.com - September 19 at 1:52 PMScilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the ...bakersfield.com - September 15 at 10:14 AMOramed and HTIT to form joint venture for oral drug productspharmaceutical-technology.com - August 3 at 7:38 AMOramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globallyfinance.yahoo.com - August 2 at 11:08 AMOramed Pharmaceuticals, Inc.jp.reuters.com - July 25 at 12:37 PMTaking a Closer Look At Oramed Pharmaceuticals Inc. (ORMP) Following Its Recent Tradeknoxdaily.com - July 4 at 8:28 PMInvesting in Oramed Pharmaceuticals Inc. (ORMP): What You Must Knowknoxdaily.com - June 26 at 9:08 AMOramed Pharmaceuticals Inc. (ORMP) may enjoy gains as insiders got busy in the recent daysknoxdaily.com - June 20 at 3:22 PMOramed to Present at the 83rd American Diabetes Association Conferencefinance.yahoo.com - June 20 at 10:21 AMOramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plansfinance.yahoo.com - June 17 at 2:50 PMORMP’s short interest surges to 0.92 million sharesknoxdaily.com - June 16 at 6:13 PMORMP Stock Sees Surge of Approximately 0.25% in Last Five Daysknoxdaily.com - June 8 at 8:08 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcorda TherapeuticsNASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Capital Senior LivingNYSE:CSUCapital Senior Living Corp. engages in the operation of senior housing communities. Its senior living options include independent living, assisted living, and memory care. The company was founded in 1990 and is headquartered in Dallas, TX.Oramed PharmaceuticalsNASDAQ:ORMPOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.